Concepts (58)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Motor Activity | 3 | 2016 | 51 | 0.240 |
Why?
|
| Behavior, Animal | 3 | 2015 | 20 | 0.240 |
Why?
|
| Morphine | 3 | 2013 | 12 | 0.230 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2015 | 8 | 0.210 |
Why?
|
| Cerebral Cortex | 2 | 2015 | 25 | 0.210 |
Why?
|
| HIV-1 | 2 | 2015 | 59 | 0.210 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2016 | 161 | 0.150 |
Why?
|
| Animals | 7 | 2016 | 978 | 0.150 |
Why?
|
| Rats | 6 | 2015 | 233 | 0.150 |
Why?
|
| Impulsive Behavior | 2 | 2016 | 5 | 0.150 |
Why?
|
| Corpus Striatum | 2 | 2016 | 15 | 0.150 |
Why?
|
| Analgesics, Opioid | 3 | 2013 | 34 | 0.150 |
Why?
|
| Mianserin | 2 | 2016 | 2 | 0.130 |
Why?
|
| Globus Pallidus | 2 | 2013 | 2 | 0.130 |
Why?
|
| Benzothiazoles | 1 | 2016 | 1 | 0.130 |
Why?
|
| Dopamine Agonists | 1 | 2016 | 7 | 0.130 |
Why?
|
| Risk-Taking | 1 | 2016 | 4 | 0.130 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 24 | 0.120 |
Why?
|
| Synaptic Transmission | 1 | 2015 | 7 | 0.120 |
Why?
|
| Dopamine | 1 | 2015 | 14 | 0.120 |
Why?
|
| Choice Behavior | 1 | 2015 | 5 | 0.120 |
Why?
|
| Cocaine-Related Disorders | 1 | 2015 | 5 | 0.110 |
Why?
|
| Neurocognitive Disorders | 1 | 2015 | 9 | 0.110 |
Why?
|
| Cocaine | 1 | 2015 | 14 | 0.110 |
Why?
|
| Male | 6 | 2016 | 1781 | 0.110 |
Why?
|
| HIV Infections | 1 | 2015 | 95 | 0.110 |
Why?
|
| Receptors, AMPA | 1 | 2013 | 5 | 0.100 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2013 | 7 | 0.100 |
Why?
|
| Brain Chemistry | 1 | 2013 | 11 | 0.100 |
Why?
|
| Methamphetamine | 1 | 2013 | 10 | 0.100 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2013 | 1 | 0.100 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Brain | 1 | 2015 | 197 | 0.100 |
Why?
|
| Morphine Dependence | 1 | 2012 | 1 | 0.100 |
Why?
|
| Conditioning, Operant | 1 | 2012 | 2 | 0.100 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2012 | 2 | 0.100 |
Why?
|
| Calcium Channels, L-Type | 1 | 2012 | 29 | 0.100 |
Why?
|
| Self Stimulation | 2 | 2016 | 2 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 167 | 0.050 |
Why?
|
| Oxidopamine | 1 | 2016 | 1 | 0.030 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2016 | 2 | 0.030 |
Why?
|
| Delay Discounting | 1 | 2016 | 2 | 0.030 |
Why?
|
| Antiparkinson Agents | 1 | 2016 | 4 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 23 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 82 | 0.030 |
Why?
|
| Hypothalamus | 1 | 2015 | 1 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2015 | 25 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2013 | 1 | 0.030 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2013 | 23 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 9 | 0.030 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 9 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2013 | 19 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2013 | 2 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 31 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 32 | 0.020 |
Why?
|
| Reward | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cues | 1 | 2012 | 6 | 0.020 |
Why?
|